SAN DIEGO — Improvements in ambulatory navigation, light sensitivity and visual field continue to be maintained at 4 years of a phase 3 trial of Luxturna in patients with biallelic RPE65 mutation-associated retinal dystrophy, Arlene V. Drack, MD, said at the American Association for Pediatric Ophthalmology and Strabismus annual meeting.
In the trial, for which Drack is a clinical investigator, patients were enrolled 2:1 in the treatment arm with voretigene neparvovec-rzyl (Spark Therapeutics) and to a control arm in which the same treatment was delayed for 1 year.
None of (Read more...)
Uncategorized